



STS Congenital Heart Surgery Data Summary
All Patients

Duke Clinical Research Institute

STS Period Ending 06/30/2018

Table 1: All Patients number submitted, in analysis, and operative mortality

| | Last 1 Year Jul 2017 - Jun 2018 | STS | Last Four Years Jul 2014 - Jun 2018 |
|--|------------------------------------|-----|--|
| Number of Operations/Patients | | | |
| Operations Submitted | 38,246 | | 157,394 |
| Operations in Analysis ¹ | 29,486 | | 122,459 |
| Patients in Analysis ² | 24,400 | | 101,757 |
| Operative Mortality³ | | | |
| Number of Mortalities | 578 | | 2,687 |
| Number Eligible | 22,233 | | 92,588 |
| Mortality Percent | 2.6 | | 2.9 |
| Mortality (95% CI) | (2.4 , 2.8) | | (2.8 , 3.0) |

¹Analysis includes only operations classified as "CPB" or "No CPB, Cardiovascular"

²Patient Numbers represent distinct patient admissions

³Mortality numbers are patient-based only for admission in the analysis population at sites with adequate mortality data



**STS Congenital Heart Surgery Data Summary
All Patients**

 Duke Clinical Research Institute

STS Period Ending 06/30/2018

Table 2: Primary diagnosis, 35 Most Frequent for All Patients, Last 4 Years (Jul 2014 - Jun 2018)

| Primary Diagnosis | N | STS | % of All |
|---|-------|-----|----------|
| VSD, Type 2 (Perimembranous) (Paramembranous) (Conoventricular) | 7,658 | | 6.3% |
| Open sternum with open skin (includes membrane placed to close skin) | 7,185 | | 5.9% |
| Hypoplastic left heart syndrome (HLHS) | 7,160 | | 5.8% |
| Patent ductus arteriosus | 5,180 | | 4.2% |
| ASD, Secundum | 4,893 | | 4.0% |
| TOF, Pulmonary stenosis | 4,735 | | 3.9% |
| Coarctation of aorta | 4,328 | | 3.5% |
| AVC (AVSD), Complete (CAVSD) | 4,127 | | 3.4% |
| Pulmonary insufficiency | 2,895 | | 2.4% |
| Cardiac, Other | 2,633 | | 2.2% |
| Aortic stenosis, Subvalvar | 2,370 | | 1.9% |
| Single ventricle, Tricuspid atresia | 2,119 | | 1.7% |
| TGA, IVS | 2,012 | | 1.6% |
| Vascular ring | 1,928 | | 1.6% |
| Conduit failure | 1,887 | | 1.5% |
| Miscellaneous, Other | 1,824 | | 1.5% |
| Pulmonary atresia, VSD (Including TOF, PA) | 1,729 | | 1.4% |
| Mitral regurgitation | 1,551 | | 1.3% |
| Single ventricle, DILV | 1,545 | | 1.3% |
| Aortic insufficiency | 1,490 | | 1.2% |
| Pulmonary atresia, IVS | 1,423 | | 1.2% |
| ASD, Sinus venosus | 1,417 | | 1.2% |
| Aortic arch hypoplasia | 1,349 | | 1.1% |
| TGA, VSD | 1,342 | | 1.1% |
| Cardiomyopathy (including dilated, restrictive, and hypertrophic) | 1,313 | | 1.1% |
| Arrhythmia, Pacemaker, Indication for replacement | 1,245 | | 1.0% |
| AVC (AVSD), Partial (incomplete) (PAVSD) (ASD, primum) | 1,228 | | 1.0% |
| Single ventricle, Heterotaxia syndrome | 1,168 | | 1.0% |
| TOF | 1,163 | | 0.9% |
| Aortic stenosis, Valvar | 1,147 | | 0.9% |
| DORV, TGA type | 1,062 | | 0.9% |
| Pulmonary atresia, VSD-MAPCA | 992 | | 0.8% |
| Coronary artery anomaly, Anomalous aortic origin of coronary artery (AAOCA) | 968 | | 0.8% |
| Truncus arteriosus | 945 | | 0.8% |
| Ebstein's anomaly | 945 | | 0.8% |

STS Congenital Heart Surgery Data Summary
All Patients

Duke Clinical Research Institute

STS Period Ending 06/30/2018

Table 3: Primary procedure, 35 Most Frequent for All Patients, Last 4 Years (Jul 2014 - Jun 2018)

| Primary Procedure | N | % of All | STS |
|---|-------|----------|---------|
| | | | % Mort. |
| Delayed sternal closure | 9,343 | 8.3% | 0.2% |
| VSD repair, Patch | 7,091 | 6.3% | 0.6% |
| Mediastinal exploration | 3,958 | 3.5% | 0.5% |
| ASD repair, Patch | 3,637 | 3.2% | 0.2% |
| AVC (AVSD) repair, Complete (CAVSD) | 3,107 | 2.8% | 2.5% |
| Norwood procedure | 2,816 | 2.5% | 13.7% |
| Pacemaker implantation, Permanent | 2,602 | 2.3% | 0.9% |
| Bidirectional cavopulmonary anastomosis (BDCPA) (bidirectional Glenn) | 2,546 | 2.3% | 1.8% |
| PA banding (PAB) | 2,454 | 2.2% | 7.0% |
| Coarctation repair, End to end, Extended | 2,423 | 2.2% | 1.3% |
| RVOT procedure | 2,355 | 2.1% | 1.1% |
| TOF repair, Ventriculotomy, Transanular patch | 2,300 | 2.1% | 1.7% |
| Aortic arch repair | 2,222 | 2.0% | 2.9% |
| PA, reconstruction (plasty), Branch, Central (within the hilar bifurcation) | 2,132 | 1.9% | 1.3% |
| Shunt, Systemic to pulmonary, Modified Blalock-Taussig Shunt (MBTS) | 1,973 | 1.8% | 6.8% |
| Fontan, TCPC, External conduit, Fenestrated | 1,853 | 1.7% | 1.2% |
| Transplant, Heart | 1,834 | 1.6% | 3.9% |
| Arterial switch operation (ASO) | 1,813 | 1.6% | 2.1% |
| Valvuloplasty, Mitral | 1,754 | 1.6% | 1.3% |
| Pacemaker procedure | 1,729 | 1.5% | 0.3% |
| Valve replacement, Pulmonic (PVR) | 1,641 | 1.5% | 0.2% |
| Vascular ring repair | 1,619 | 1.4% | 0.2% |
| Conduit placement, RV to PA | 1,601 | 1.4% | 1.6% |
| TAPVC repair | 1,504 | 1.3% | 6.2% |
| Aortic stenosis, Subvalvar, Repair | 1,325 | 1.2% | 0.2% |
| Fontan, TCPC, External conduit, Nonfenestrated | 1,284 | 1.1% | 0.5% |
| Valvuloplasty, Tricuspid | 1,255 | 1.1% | 1.5% |
| Superior Cavopulmonary anastomosis(es) + PA reconstruction | 1,254 | 1.1% | 1.9% |
| TOF repair, Ventriculotomy, Nontransanular patch | 1,243 | 1.1% | 1.0% |
| PDA closure, Surgical | 1,216 | 1.1% | 4.2% |
| Valve replacement, Mitral (MVR) | 1,163 | 1.0% | 3.0% |
| TOF repair, No ventriculotomy | 1,052 | 0.9% | 0.4% |
| Shunt, Systemic to pulmonary, Central (shunt from aorta) | 986 | 0.9% | 7.7% |
| Conduit reoperation | 896 | 0.8% | 0.3% |
| Aortic arch repair + VSD repair | 889 | 0.8% | 2.6% |